 |
PRESS RELEASE
For Immediate Release
EBD Group and Scrip World Pharmaceutical News collaborate to provide expert guidance on "Bio-Pharma Partnering"
Carlsbad, CA, and London, UK, November 8, 2007 - EBD Group, the leading partnering firm for the global
biotechnology industry, and Scrip World Pharmaceutical News, the leading provider of news and analysis for the global pharmaceutical
and biotechnology industries, today announced their collaboration to publish Bio-Pharma Partnering magazine. This new global magazine
will be an indispensable resource for a wide range of biotechnology and pharmaceutical industry leaders in multiple markets,
providing the insight needed to develop and execute successful partnering strategies.
Bio-Pharma Partnering explores bio-pharmaceutical partnerships from multiple angles, analysing the latest trends that affect the
business of partnering, looking at the various factors at play in dealmaking, spotlighting hot therapeutic areas of innovation,
and providing clarity on the legal and regulatory requirements that govern this vibrant field.
Written by the Scrip team and featuring comment and contributions from industry experts, the inaugural issue of Bio-Pharma Partnering
will include:
The origins of partnering
A select group of industry experts looks back over the history of bio-pharma partnering and talks up the landmark deals that have
helped shape the industry as we know it today.
The proof-of-concept challenge
As pharma companies look ever further upstream for assets to license, biotechs need to respond by striking effective partnerships
to reach early proof-of-concept.
Deconstructing early-stage assets
A 'virtual company' approach could provide a new way of determining fair deal terms in licensing contracts, offering particular value
to early-stage partnering negotiations between biotechs and academia.
The lure of Japan
The relaxation of regulatory guidelines has led the seemingly impenetrable Japanese biopharmaceutical industry finally to open its
doors to western rivals.
New rules at the USPTO: change for the better?
The US Patent and Trademark Office has issued a set of rules for both newly filed and many previously filed applications, with major
implications for the biotech industry.
Interview
Meet Dr John Maraganore, the man at the helm of Alnylam Pharmaceuticals, a pioneer in the field of RNA interference.
"Strategic collaborations are increasingly recognised as the lifeblood of the biotech industry, and partnering has become essential to
maintaining a competitive edge. From drug discovery alliances through to product and technology platform licences, it's clear that
partnering in the biopharmaceutical industry is growing in strategic importance," said Jenefer Trevena, Managing Editor, Scrip
Publishing. "In seeking to develop Bio-Pharma Partnering we realised the need for a partner as dynamic as the biopharmaceutical
sector that the magazine represents. EBD Group fits this bill perfectly, as a highly respected leader in the biotech partnering
arena, as well as an organiser of the premier biotech industry partnering conferences, BIO-Europe and BIO-Europe Spring."
"Partnering offers numerous opportunities and advantages to all participants. Yet the growth of partnering activity has also created
unique challenges for businesses. In order to fully benefit from partnering, firms need to know about potential partnerships and
possible pitfalls, and must keep up to speed on the events and trends impacting future partnering strategies," said Carola Schropp,
Managing Partner, EBD Group. "We are excited to be working with Scrip, the world's leading provider of independent pharmaceutical
news and commentary, to create an invaluable industry resource on how to excel in the complex world of biotech partnering."
The first issue of Bio-Pharma Partnering, due out in December, will be available to Scrip's 100,000+ readers worldwide and free to
download on www.scripsupplements.com or by request to the publisher.
The magazine will also be available to EBD Group's worldwide customers, including delegates of BIO-Europe, BIO-Europe Spring and
BioDevice Partnering. A free download will be available on www.ebdgroup.com.
About Scrip World Pharmaceutical News
Scrip World Pharmaceutical News is the leading provider of news and analysis for the global pharmaceutical and biotechnology
industries. With its network of journalists in Europe, the US and Asia, Scrip updates its subscribers daily via the website or direct
email alert, and twice weekly in a print or PDF newsletter. Pharmaceutical companies the world over rely on Scrip for timely,
comprehensive and accurate information on all issues affecting their business.
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, numerous firms have leveraged EBD
Group's partnering conferences, technology and services to identify opportunities and develop the strategic relationships that drive
their business successfully forward.
EBD Group's conferences (run in collaboration with leading industry partners and international trade associations such as BIO and
Eucomed) include BIO-Europe, the world's largest stand-alone life science partnering conference; BIO-Europe Spring®; the investor
conference BioEquity Europe (co-organized with BioCentury Publications); and the medical technology partnering conference, BioDevice
partnering™. EBD Group's advanced, web-based partnering software system PartneringONE™ is also used at numerous third-party
events around the world. Outside of the conference format, EBD Group's consultants can provide hands-on assistance for firms seeking
to in- or out-license products and technologies.
EBD Group has offices in San Diego, Munich and London. For more information visit www.ebdgroup.com
Contacts:
Constantine Theodoropulos
+1 617.292.7319
ctheodoropulos[at]ebdgroup.com
Florian Schoenhammer
+49 89 2388 756-0
fschoenhammer[at]ebdgroup.com
Paul Thoroughgood
+44 (0) 20 7017 6929
paul.thoroughgood[at]informa.com
|
|
